| Literature DB >> 29795641 |
Annett Hölsken1, Marc Schwarz2,3, Clarissa Gillmann2, Christina Pfister1, Michael Uder2, Arnd Doerfler3, Michael Buchfelder4, Sven Schlaffer4, Rudolf Fahlbusch5, Rolf Buslei6, Tobias Bäuerle2.
Abstract
PURPOSE: Adamantinomatous craniopharyngiomas (ACP) as benign sellar brain tumors are challenging to treat. In order to develop robust in vivo drug testing methodology, the murine orthotopic craniopharyngioma model (PDX) was characterized by magnetic resonance imaging (MRI) and histology in xenografts from three patients (ACP1-3).Entities:
Mesh:
Substances:
Year: 2018 PMID: 29795641 PMCID: PMC5993109 DOI: 10.1371/journal.pone.0197895
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient-specific origin of xenografts and study results.
| Clinical data | Murine PDX | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary tumor | gender | age | CTNNB1 mutation | PDX | Estimated vital tumor cells within the lesion (%) | Average vitality | T2 –Tumor Volume (mm3) | CETV (mm3) | ADC (10-3mm2/s) | PE (AU) (from AUC) | AUC (AU) | TTP (s) |
| m | 9 | codon 33 TCT(Ser)>TTT(Phe) | M1 | <10 | <10% | 0.775 | 0.391 | 289.96 | nap | nap | nap | |
| M2 | <10 | 0.398 | 0.528 | 304.00 | nap | nap | nap | |||||
| M3 | <10 | 2.051 | 1.809 | 580.02 | nap | nap | nap | |||||
| M4 | <10 | 0.1889 | 0.000 | 592.76 | nap | nap | nap | |||||
| M5 | <10 | 0.143 | 0.138 | nap | nap | nap | nap | |||||
| M6 | <10 | 0.189 | 0.000 | 197.88 | nap | nap | nap | |||||
| M7 | ≤15 | 0.389 | 0.394 | 542.72 | nap | nap | nap | |||||
| f | 28 | codon 37 TCT(Ser)>TGT(Cys) | M1 | 18 | 41% | 3.690 | 3.639 | 636.32 | 3.243 | 1857.544 | 688.67 | |
| M2 | 65 | 2.267 | 0.915 | 823.02 | 1.241 | 413.112 | 688.68 | |||||
| M3 | 45 | 3.397 | 3.335 | 653.87 | 4.368 | 2894.490 | 328.32 | |||||
| M4 | 35 | 4.319 | 4.689 | 649.76 | 3.168 | 2002.002 | 711.70 | |||||
| M5 | 50 | 4.419 | 4.662 | 868.63 | 4.169 | 2680.921 | 633.62 | |||||
| M6 | 25 | 3.239 | 3.842 | 955.21 | 5.035 | 3243.652 | 547.53 | |||||
| M7 | 35 | 2.155 | 2.435 | 701.18 | 2.651 | 1665.557 | 633.62 | |||||
| M8 | 25 | 4.238 | 3.806 | 755.256 | 2.536 | 1640.649 | 484.47 | |||||
| M9 | 70 | 3.783 | 3.678 | 707.828 | 2.038 | 1363.598 | 163.15 | |||||
| M10 | 45 | 2.101 | 2.351 | 653.96 | 2.174 | 1448.397 | 328.32 | |||||
| m | 56 | codon 33 TCT(Ser)>TGT(Cys) | M1 | 35 | ~26% | 0.563 | 0.000 | 431.93 | 0.801 | 447.167 | 203.19 | |
| M2 | <10 | 0.257 | 0.1381 | nap | 0.326 | 165.496 | 38.030 | |||||
| M3 | 15 | nap | 0.000 | 559.18 | 0.405 | 93.178 | 7.000 | |||||
| M4 | 20 | 1.510 | 1.532 | 843.64 | 1.567 | 988.460 | 273.260 | |||||
| M5 | 18 | 1.520 | 1.392 | 588.49 | 1.863 | 1058.330 | 70.060 | |||||
| M6 | <10 | 0.928 | 0.379 | 622.00 | 0.717 | 315.002 | 46.040 | |||||
| M7 | 55 | 1.905 | 1.428 | 838.65 | 0.573 | 296.725 | 7.000 | |||||
| M8 | 45 | 0.405 | 0.107 | 404.053 | 0.625 | 255.027 | 23.010 | |||||
| M9 | 45 | 1.313 | 0.475 | 284.00 | 0.660 | 462.662 | 688.680 | |||||
| M10 | <10 | nap | 0.000 | 547.56 | 1.631 | 569.779 | 22.010 | |||||
Fig 1Comparison of primary human MRI and histology with the induced model.
MR images and corresponding histology of an ACP patient (ACP2) showing the primary tumor and relapse after 145 days are illustrated in comparison with an example of a direct vital descendent of the surgically removed primary tumor specimen implanted into the nude mouse number one out of ten (ACP2 M1). T2 weighted images show a cystic component within the craniopharyngioma in the human patient (a and b; arrow) with contrast enhancement in the rim of the lesion (e and f; arrow) at baseline (a and e) as compared to 145 days later (b and f) with an increase in size over time. The craniopharyngioma xenograft in the mouse is inhomogeneous in T2 (c and d) and post contrast T1 (g and h) weighted images. The T2w hyperintense and T1 contrast enhancing areas in the tumor increase over 110 days as well (c and d; g and h). Histology of the primary tumor (i) shows similar characteristics to the descendent tumors in human (j) and in mice (k and k`) in terms of vital tumor proportions (arrow), wet keratin (asterisk) and calcification (arrowhead). Vital tumor areas (arrow, k´) in the murine graft were also identified on MRI (arrows, d and h) by T2 hyperintensity and contrast enhancing areas in T1. However, calcified regions appear hypointense (arrowhead, k´, d and h). PDX tumor volume (n = 5) defined 28 and 138 days post transplantation (dpt) in T2 weighted as well as post contrast T1 weighted images revealed a significant increase over time (p<0.05) (l).
Fig 2Comparison of patient specific engrafted tumors.
Primary (a, e and i) and descended transplanted ACP tissue (b, c, f, g, j and k) show comparable histological appearance with regressive changes e.g. wet keratin (*) and calcifications (arrowhead) with estimated vitality indicated in the magnified images. Associated T1 weighted MR images after contrast medium application (d, h and l) are shown for comparison with histological appearance.
Fig 3MRI data correlated with patient specific grafts and vitality.
a: Patient derived engrafted tumors were analyzed in terms of T2 tumor volume (T2 TV), contrast-enhancing tumor volume (CETV), apparent diffusion coefficient (ADC), area-under-the-curve (AUC), peak enhancement (PE) and time-to-peak (TTP). b: Corresponding data were also evaluated in matters of vitality with a cutoff of 15% discriminating non-vital from vital engrafted tumors. Significant differences are marked by an asterisk (*). Detailed results e.g. mean values and p-values are listed in S2 Table.